Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2784987 | 0.89 | DRD2 (0.56) | DRD4OPRL1DRD2DRD3HTR6 | |
| SCHEMBL14163184 | 0.87 | DRD4 (0.54) | DRD4DRD2DRD3HTR6HRH3 | |
| SCHEMBL2783316 | 0.86 | DRD4 (0.46) | DRD4OPRL1DRD2DRD3HTR6 | |
| SCHEMBL2781201 | 0.84 | DRD4 (0.47) | DRD4DRD2DRD3HTR6HRH3 | |
| SCHEMBL3772743 | 0.84 | NOS3 (0.46) | DRD4DRD2DRD3HTR6HRH3 | |
| SCHEMBL2783219 | 0.84 | DRD4 (0.45) | DRD4OPRL1DRD2DRD3HTR6 | |
| SCHEMBL2783029 | 0.84 | DRD4 (0.45) | DRD4DRD2DRD3HTR6HRH3 | |
| SCHEMBL2781897 | 0.84 | DRD2 (0.48) | DRD4OPRL1DRD2DRD3HTR6 | |
| SCHEMBL5502940 | 0.78 | NOS3 (0.41) | DRD4DRD2DRD3HTR6HRH3 | |
| SCHEMBL3767627 | 0.78 | DRD2 (0.44) | DRD4OPRL1DRD2DRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | claimed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | claimed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | claimed |
| CN-1997631-A | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2007-07-11 | — | — | CN | claimed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| CN-1997631-A | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2007-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | DRD2, DRD4, HTR4 | DRD4 2/4885OPRL1 22/4885DRD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.